INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress

Dr. Tesi will also discuss the results of the Phase I trial for INmune Bios drug candidate, INB03 in patients with advanced cancer.